BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Beta Bionics, Inc. (Nasdaq: BBNX) for potential securities law violations. Investors who have lost money in their Beta Bionics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/bbnx. What is this all about? Shares of Beta Bionics fell over 35% in January, after the company released preliminary Q4 2025 topline results showing new pat ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - February 24, 2026) - Faru ...

Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact name of Registrant as specified in its charter) Delaware 47-5386878 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 11 Hughes Irvine, California 92618 (Address of principal executive offices) (Zip Code) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PUR ...

IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD Cowen’s 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 am Eastern Time (7:30 am Pacific Time). A live audio webcast of the presentation will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, an ...

Core Insights - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. due to significant stock losses experienced by investors [2][4] - Beta Bionics' stock (NASDAQ: BBNX) dropped approximately 37% on January 9, 2026, following the company's announcement of lower-than-expected patient starts for the fourth quarter [4] Company Overview - Beta Bionics, Inc. is a publicly traded company listed on NASDAQ under the ticker BBNX [2] - The company has faced scrutiny regarding whether it issued misleading statements or failed to disclose critical information to investors [4] Legal Context - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3] - The firm is encouraging investors who have suffered significant losses in Beta Bionics to discuss their legal options [1][2]

For the fourth quarter, Beta Bionics reported $32.1 million in net sales , up 57% year-over-year. Saint attributed the growth to:Beta Bionics also emphasized its strategy to expand access through pharmacy reimbursement. Saint said the percentage of new patient starts through pharmacy rose to the high 20s% for full-year 2025, compared with a high single-digit percentage in the prior year, and noted the company has established formulary agreements with all major U.S. pharmacy benefit managers (PBMs).Saint sai ...

Beta Bionics, Inc. (BBNX) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $1.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +28.57%. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $0.33, delivering a surprise of +26.67%.Over the last four quarters, the company has su ...

Beta Bionics (NasdaqGM:BBNX) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsBlake Beber - Head of Investor RelationsDavid Roman - Managing Director and Co-Head Healthcare Business UnitJeffrey Cohen - Managing Director and Director of Equity ResearchJon Block - Managing DirectorMatthew Blackman - Managing DirectorSean Saint - CEOStephen Feider - CFOConference Call ParticipantsDanielle Antalfy - Senior AnalystFrank Takkinen - Senior Research AnalystJeff Johnson - Managing Director and ...

Beta Bionics (NasdaqGM:BBNX) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsBlake Beber - Head of Investor RelationsJeffrey Cohen - Managing Director and Director of Equity ResearchJon Block - Managing DirectorMatthew Blackman - Managing DirectorSean Saint - CEOStephen Feider - CFOConference Call ParticipantsDanielle Antalfy - Senior AnalystFrank Takkinen - Senior Research AnalystJeff Johnson - Managing Director and Senior Research AnalystMatthew O'Brien - Managing Director and Seni ...

Financial Data and Key Metrics Changes - For the full year 2025, Beta Bionics reported net sales of $100.3 million, representing a 54% year-over-year growth. The gross margin was 55.4%, which expanded slightly year-over-year [10][11] - In Q4 2025, the company generated $32.1 million in net sales, reflecting a 57% growth year-over-year, with a gross margin of 59%, an increase of 179 basis points year-over-year [11][12] Business Line Data and Key Metrics Changes - The company added approximately 20,000 new users in 2025, more than doubling its installed base to over 35,000 users [6][10] - In Q4, 5,592 new patient starts were recorded, a 37% increase year-over-year, with a growing percentage of new patient starts reimbursed through the pharmacy channel [11][12] Market Data and Key Metrics Changes - The percentage of new patient starts through the pharmacy channel grew to the high 20s% for the full year 2025, compared to a high single-digit percentage in the previous year [10][12] - In Q4, approximately 69% of new patient starts came from individuals who previously used multiple daily injections, indicating an expansion of the market for insulin pumps [16] Company Strategy and Development Direction - Beta Bionics aims to revolutionize diabetes care by improving access and outcomes for people with diabetes through innovative products like the iLet and the upcoming Mint patch pump [5][9] - The company has established formulary agreements with major pharmacy benefit managers, enhancing user access to the iLet and its consumables at lower out-of-pocket costs [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to continue expanding the pump market and capturing market share, with revenue guidance for 2026 set at $130 million to $135 million [18][19] - The company acknowledged challenges related to seasonality in the insulin pump market, particularly the expected decline in Q1 2026 revenue compared to Q4 2025 [21][23] Other Important Information - The company received a Warning Letter from the FDA regarding quality system observations, which management is actively addressing through remediation efforts [29][30] - Beta Bionics is progressing with its R&D initiatives, including the development of the Mint patch pump and the bihormonal system, with significant milestones achieved in clinical trials [40][41] Q&A Session Summary Question: Can you discuss the level of conservatism in the 2026 guidance? - Management refrained from labeling the guidance as conservative but expressed confidence in meeting the communicated revenue targets, considering potential headwinds from pharmacy channel performance [46][47] Question: What is the outlook for the U.S. pump market in Q4? - Management did not provide specific insights on market share due to competitors not yet reporting their earnings [53][55] Question: How will the expansion of sales territories impact market coverage? - The company plans to add at least 20 new sales territories in 2026, with a significant portion of this expansion occurring in the first half of the year [56][60] Question: What are the expectations for Q1 2026 revenue? - Management indicated that Q1 2026 is expected to see a larger decline in revenue compared to the previous year, influenced by unique product launches in Q4 2024 [63][68] Question: How does the company address concerns regarding hypoglycemia? - Management stated that the rates of hypoglycemia with the iLet are consistent with clinical trials and significantly lower than ADA guidelines, emphasizing the safety of their product [85][86]